Special Issue "Medicinal Importance of Ruthenium Compounds"
Deadline for manuscript submissions: 31 May 2019
Prof. Dr. Iztok Turel
University of Ljubljana, Faculty of Chemistry and Chemical Technology, Vecna pot 113, 1000 Ljubljana, Slovenia
Website | E-Mail
Fax: +386 1 2419220
Interests: bioinorganic chemistry; metal ions; biologically active compounds; metal based drugs; quinolones; guanine derivatives; diketonates; hydroxyquinolines; pyrithiones; ruthenium chemistry
Forty years ago (1978), cisplatin was approved by the FDA (Food and Drug Administration) for use in certain types of cancers and this drug is still used in clinical practice. Without any doubt, for many years platinum complexes were the most intensely studied from all potential metal-based anticancer drugs; however, in the last few decades, an increasing number of papers have been published exploring the medicinal properties of another platinum group metal—ruthenium. Some of the reasons why the alternatives for platinum complexes were explored were resistance development and the severe side effects of platinum drugs. Ruthenium(III) compounds isolated in the labs of Alessio (NAMI-A) and Keppler (KP1019, and more soluble analog KP1339) have, long ago, entered clinical trials. It is encouraging that a photodynamic therapy (PDT) agent based on Ru(II), namely TLD-1433, has also recently entered clinical trials. Several other ruthenium compounds are involved in preclinical level studies as potential chemotherapeutics. On the other hand, radiotherapy with ruthenium-106 was also found to be effective for the treatment of malignant iris melanoma.
However, ruthenium compounds were not only explored as anticancer agents, but also as potential antimicrobial drugs, as potential drugs for neurodegenerative diseases, as inhibitors of several enzymes, as immunosuppressants and as nitric oxide scavengers.
Apart from the biological activity of ruthenium complexes, their physico-chemical properties (e.g., photophysical effects) can be used for diagnostic properties. Ruthenium luminophores can be used as highly effective probes for cell imaging in microscopy. Moreover, theranostics (a combination of therapy and diagnostics) is very popular and luminescent ruthenium complexes are also tested for such types of applications.
This Special Issue will include a selection of research and review articles to collect and disseminate contributions in the field of ruthenium medicinal chemistry.
Prof. Dr. Iztok Turel
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Uses of ruthenium in:
- metal-based drugs
- metal–drug interactions
- anticancer drugs
- antimicrobial agents
- neurodegenerative diseases
- enzyme inhibition
- photophysical properties
- photodynamic therapy